BERLIN (GenomeWeb) – Laboratories at 11 institutions in Europe, Canada, and Japan have tested Thermo Fisher Scientific's Oncomine Lung cfDNA assay and found that it can detect low-level mutations in circulating free DNA control samples with high sensitivity and specificity.

Yesterday at the Association for Molecular Pathology AMP Global Congress in Berlin, Claudia Vollbrecht of the Institute of Pathology at Charité University Medicine Berlin presented the results of the study, which was conducted by the OncoNetwork Consortium, a network of researchers organized by Thermo.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Mar
08
Sponsored by
Swift Biosciences

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.

Mar
13

This webinar will share how clinical genetics labs can integrate cytogenetics and molecular data to assess abnormalities using a single sample on a single workflow platform.

Apr
03

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research.